Claritas Rx’s Post

Opyl (ASX: OPL) Executive Chairman, Saurabh Jain, was recently featured on the Innovation and Leadership podcast with Jess Larsen. Jess, co-founder of a biotech venture capital firm focused on preventive medicines and longevity, and founder of Graystoke Investments, and Graystoke Networks, brings his unique perspective to the table. 🔉 Listen now: https://lnkd.in/g7Dhsu6r In this insightful conversation, Saurabh shares how TrialKey is revolutionising clinical trials through advanced AI and predictive analytics. They discussed how TrialKey unlocks hidden insights from over 400,000 clinical trials by analysing them across 700 variables using Natural Language Processing to convert unstructured data into actionable intelligence. 📈 A key discussion point was how trial phase data showing success or failure is a critical inflection point for mid to smaller #biofund stock prices. TrialKey's insights can help #biotech and #biopharma investors navigate which stocks are likely to increase in value. 🔎 They also explored the use of TrialKey in analysing Plasminogen Activator Inhibitor-1 (PAI-1) and competitors' efforts on conditions like Crohn’s disease. By understanding how you rank against competitors in probability of success and using #TrialGen to design optimal trials, TrialKey provides a significant advantage. They highlighted how TrialKey is the market leader in AI prediction and optimisation software, thanks to our comprehensive analysis of the most variables, detailed data presentation, insights, and trial simulations. One key takeaway from Jess during the episode is that while you can always find good scientists, good drug developers are harder to come by. The groundbreaking technology of TrialKey could revolutionise the pharmaceutical industry and accelerate the development of life-saving drugs. The sheer volume of medical information makes it impossible for any one person to know it all, which is why an AI tool like TrialKey is revolutionary. Book a demo: https://lnkd.in/g9rJtUBm Marketing, investor, and speaking enquiries: bernice.averion@opyl.ai #clinicaltrials #AI #Pharma #investments #asx #opyl #trialkey

Is #GenAI the silver bullet for the #pharmaceutical industry's innovation drought? 🤔 A recent McKinsey & Company report intriguingly suggests its shift from hype to actionable insights, with a potential to unleash $60 billion to $110 billion annually. But, as we marvel at Generative AI's promise to revolutionize #drugdiscovery, #clinicaltrials, and more, we must also tread cautiously. The excitement around its potential shouldn't overshadow the considerable challenges of implementation, including technological scalability and the need for strategic realignment within organizations. In my view, balancing optimism with a critical eye towards these hurdles is essential. As we chart this new territory, the real question becomes: can the industry adapt quickly enough to fully harness Generative AI's potential? The excitement around its potential shouldn't overshadow the considerable challenges of implementation, including technological scalability and the need for strategic realignment within organizations. I'd love to hear your thoughts on balancing #innovation with realism in the journey of adopting Generative AI in pharma. Let's discuss! 💡👇 #DigitalHealth #MedTech #HealthcareTechnology

Integrating AI to ease the long and costly drug discovery process. Thanks Dr. Andrée Bates!!!

From Research & Development to Business Development, Licensing, and Clinical Trials, AI is revolutionising every stage of the process. -AI analyses massive datasets to expedite drug discovery, generates novel drug candidates via machine learning, and optimizes clinical trial designs. -Collaborations between big tech firms and pharma giants are harnessing AI's potential to drive innovation and efficiency across the industry. -There is the tremendous transformative potential of innovations like digital twins in revolutionising clinical trials, offering new insights and efficiencies to enhance patient outcomes. Discover real-world examples of AI's pivotal role in drug discovery, showcasing its power to address pressing global challenges on The AI For Pharma Growth Podcast here: https://lnkd.in/dQrBJT-f #pharmaceuticalmanufacturing #pharmacompany #pharmaceuticalinnovation #pharma #pharmaceuticalmarketing

From Research & Development to Business Development, Licensing, and Clinical Trials, AI is revolutionising every stage of the process. -AI analyses massive datasets to expedite drug discovery, generates novel drug candidates via machine learning, and optimizes clinical trial designs. -Collaborations between big tech firms and pharma giants are harnessing AI's potential to drive innovation and efficiency across the industry. -There is the tremendous transformative potential of innovations like digital twins in revolutionising clinical trials, offering new insights and efficiencies to enhance patient outcomes. Discover real-world examples of AI's pivotal role in drug discovery, showcasing its power to address pressing global challenges on The AI For Pharma Growth Podcast here: https://lnkd.in/duv-EiYP #pharmaceuticalmanufacturing #pharmacompany #pharmaceuticalinnovation #pharma #pharmaceuticalmarketing

In our quest to improve the lives of patients, AI and ML are becoming important allies. The question isn't whether we can improve society through clinical research, but rather how we can do it more efficiently. I was Inspired by @NajatKhan's insights on AI's potential in pharma! One of the most promising trends in this field is the application of AI and ML in drug discovery. These technologies are transforming the way we identify potential compounds, speeding up the process, and reducing costs. This means quicker access to life-saving medications for those in need. 🌍💊 #PharmaInnovation #PatientAdvocacy #PatientCare

"Snackable AI" a fantastic opportunity to accelerate business. However, harder to realize than many hope. It requires fast, consistent, high quality data access from all relevant sources. Obviously department overarching, unified and connected platforms enable this in a unique way but that means companies have to move away from siloed/"use case driven" IT decisions and embrace platform decisions. Something that only can be realized with commitment from the executive board, like Sanofi shows below.

At Sanofi, we’re “all in” on AI. Now, I realize I’m not the first CEO to make this claim, but it’s true that every day I get more excited about its potential for our industry. So what does “all in” actually look like for a company like ours? For sure it means doubling down on “expert AI” by giving our R&D teams bespoke tools and technologies to find the next breakthrough medicines and vaccines for patients. But we’re going further, to become the first pharma company powered by AI at scale. To do this, we’re leveraging “snackable AI” across the organization. Snackable AI is about democratizing access to company data to put better decision intelligence in the hands of all our employees – from manufacturing to finance to quality, and many in between. Because, when they start to add up, better everyday decisions will help us transform the practice of medicine for people faster, and better, than ever before. #AI #Science #Innovation http://spkl.io/60434m1Ez

This is so inspiring!! Paul Hudson is probably one of the the first few CEOs who actually understands where #GenAI is going and more importantly has defined a simple and effective strategy to empower his organization by making it accessible. Go #Sanofi! #snackableai I love this, and I'm borrowing the hashtag if Clem Delangue 🤗 hasn't already! #ai #innovation #management #strategy

💊 Big Pharma is leveraging the power of artificial intelligence (AI) to accelerate clinical trials and potentially save millions of dollars. By using AI, major drugmakers like Amgen, Bayer, and Novartis are able to quickly find patients for trials and reduce the number of participants needed. This not only speeds up drug development but also improves efficiency and cost-effectiveness. The use of AI in drug trials is a growing trend, with the U.S. FDA receiving over 300 applications that incorporate AI or machine learning in drug development. It's fascinating to see how technology is revolutionizing the healthcare sector! Check out the full article here: https://lnkd.in/gdABs88g #laboratories #digitaltransformation #pharmaceutcial #ai #growth